SHPGY Related
-
Impax (IPXL), Shire (SHPGY) Settle Litigation Tied to Generic Adderall XR
-
Barclays Upgrades Shire plc (SHPGY) to Overweight
-
Shire plc (SHPGY) Reports Statistically Significant Data for VPRIV in Type 1 Gaucher Disease
-
Notable Analyst Rating Changes 06/26: (JPM) (SHPGY) (PBI) Upgraded; (CTSH) (MS) (DOW) Downgraded
-
Societe Generale Upgrades Shire plc (SHPGY) to Buy
-
Morning Movers 06/25: (JAX) (LEE) (MDGN) Higher; (VTUS) (GEOY) (MNTA) (KEX) Lower
-
Canaccord Genuity on Life Sciences: Generic Adderall XR Approval Offers Several Cross-stock Implications
-
Nomura Securities Maintains a 'Buy' on Shire plc (SHPGY); FDA Approved Generic Version of Adderall-XR
-
Actavis Adderall XR Approval Positive for Watson Pharm (WPI), Negative for Impax Lab (IPXL)
-
Shire plc (SHPGY) Gets FDA Response for All Adderall XR ANDAs
-
Pre-Open Winners 6/13: (USU) (KITD) (DELL) Higher (more...)
-
Leerink Swann Upgrades Shire plc (SHPGY) to Outperform; Market Opportunity Looks Compelling
-
BioMarin (BMRN) Higher as Takeover Chatter Swirls
-
Susquehanna Upgrades Shire plc (SHPGY) to Positive
-
Goldman Sachs Says Buy Shire plc (SHPGY) On Recent Weakness, Keeps Top Rating
-
Shire pic (SHPGY) Reports In-Line Q1 EPS; Reaffirms Outlook
-
Rockwell Medical (RMTI) Adds Raymond Pratt, M.D., as Chief Medical Officer
-
Shire (SHPGY) Adds New Technology Platform, Phase 2 Product Candidate to Regenerative Unit
-
Leerink Swann Starts Shire plc (SHPGY) at Market Perform; Growth Already Priced In; Wait for Better Entry
-
Deutsche Bank Maintains a 'Buy' on Shire plc (SHPGY) Despite Disappointing Lialda Diverticulitis Ph 3 Results
-
Shire plc (SHPGY) Says SPD476 Miss Primary Endpoint in PREVENT2
-
Shire plc (SHPGY) Reaffirms Commitment to Two More Midodrine HCl Trials
-
Notable Mergers and Acquisitions of the Day 03/15: (CSCO) (RVSN) (SHPGY)
-
Shire plc (SHPGY) to Acquire FerroKin BioSciences in $100M Deal + ~$225M of Milestones
-
Shire (SHPGY) to Withdraw BLA for Replagal, FDA Needs Controlled Trials for Approval
-
Shire plc (SHPGY) to Initiate Two Phase 4s for Vyvanse Caps vs. Concerta
-
Shire plc (SHPGY) Gets EMA Approval for VPRIV Production
-
Baird Maintains an 'Outperform' on Shire plc (SHPGY); Like Clockwork, Another Positive Update & Outlook
-
Shire pic (SHPGY) Tops Q4 EPS by 14c
-
Trading Radar for 02/09: Sirius XM (SIRI), PepsiCo (PEP), Expedia (EXPE), Dunkin' Brands (DNKN), Linkedin (LNKD), Activision (ATVI) Report
-
Shire plc (SHPGY) Gets FDA Approval for Adult ADHD Medication Vyvanse
-
Unusual 11 Midday Movers 02/01: (KTCC) (MGAM) (COCO) (SGMO) Higher; (HVB) (JDAS) (IXYS) Lower
-
Sangamo (SGMO) Shares Rise Amid Deal with Shire (SHPGY) to Develop Therapeutics Treatment for Hemophilia
-
Shire (SHPGY) Grabs U.S. Rights to Resolor
-
Shire plc (SHPGY) Venvanse Accepted for Review by MHRA, U.K.
-
Shire (SHPGY) President Michael Cola Sells ~$1.90M of ADS Holdings
-
Shire plc (SHPGY) Reports Vyvanse Met Primary Endpoint in Phase II for MDD Treatment
-
Shire (SHPGY) Announces Agreement with FDA for Additional Clinical Trials on ProAmatine
-
Piper Jaffray Upgrades Shire plc (SHPGY) to Overweight
-
Shire pic (SHPGY) Misses Q3 EPS by 2c; Revs Strong
-
Trading Radar for 10/28: Chevron (CVX), CIGNA (CI), Barnes (B), Merck (MRK), Newell Rubbermaid (NWL) Report
-
SocGen Upgrades Shire plc (SHPGY) to Buy
-
Shire (SHPGY) Wins US Approval for FIRAZYR(R); ViroPharma (VPHM) Shares Moving Lower
-
Shire (SHPGY) Will Not Pursue Dermagraft as Latest Trial Did Not Meet Endpoints
-
Barclays Downgrades Shire plc (SHPGY) to Equalweight
-
Shire plc (SHPGY) Shares on the Move Following Intraday Upgrade at UBS
-
Notable Analyst Rating Changes 08/05: (CLGX) (RIG) (HD) Upgraded; (BAC) (DNR) (ILMN) Downgraded
-
William Blair Starts Shire plc (SHPGY) at Market Perform
-
BofA/Merrill Lynch Downgrades Shire plc (SHPGY) to Neutral
-
JPMorgan Downgrades Shire plc (SHPGY) to Neutral
Back to SHPGY Stock Lookup
